NINDS Neuroscience Funding Announcements

The objective of this contract is to accelerate neuroprotective therapeutics development for Parkinson’s disease (PD). PD is the second most commonly occurring neurodegenerative disease, hallmarked by the gradual loss of dopaminergic and other neurons, as well as the accumulation of insoluble aggregates. Therefore, a primary goal is to find rational treatments which can prevent progression of the disease once diagnosed, or prevent neurons from dying in individuals at risk for developing disease. It is anticipated that the award from this solicitation will be a cost reimbursement contract.